Comparative Pharmacology
Head-to-head clinical analysis: HUMALOG MIX 75 25 PEN versus NOVOLOG MIX 70 30 FLEXPEN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HUMALOG MIX 75 25 PEN versus NOVOLOG MIX 70 30 FLEXPEN.
HUMALOG MIX 75/25 PEN vs NOVOLOG MIX 70/30 FLEXPEN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Insulin analog with intermediate-acting insulin (insulin lispro protamine suspension) and rapid-acting insulin (insulin lispro). Binds to insulin receptors, activating glucose uptake, glycogen synthesis, and lipogenesis, while inhibiting gluconeogenesis and ketogenesis.
Insulin aspart is a rapid-acting insulin analog that lowers blood glucose by stimulating peripheral glucose uptake, especially by skeletal muscle and fat, and by inhibiting hepatic glucose production. It replaces endogenous insulin and has a faster onset and shorter duration than regular human insulin due to altered amino acid sequence (substitution of proline at position 28 with aspartic acid).
Subcutaneous injection. Individualized based on metabolic needs. Typical total daily insulin dose: 0.5-1 unit/kg/day divided, with Humalog Mix 75/25 given 15 minutes before meals. Starting dose: 0.2-0.3 unit/kg/day for type 1 diabetes; 0.3-0.5 unit/kg/day for type 2 diabetes. Administer twice daily: before breakfast and before dinner. Dose adjustments based on blood glucose monitoring.
Subcutaneous injection only. Initial total daily insulin dose: 0.5 to 1 unit/kg/day. Administer 70% intermediate-acting insulin aspart protamine and 30% rapid-acting insulin aspart. Typically given twice daily within 15 minutes before meals. Dose individualize based on glycemic goals.
None Documented
None Documented
Insulin lispro protamine: 13-16 hours (intermediate component); Insulin lispro: 1-2 hours (rapid component). Clinical context: Steady state achieved after 2-4 days of dosing.
0.5-1 hour for the rapid-acting insulin aspart component and 8-10 hours for the protamine-crystallized insulin aspart component. Clinical context: biphasic profile allows for both prandial and basal coverage.
Renal: 30-80% (protamine-insulin complex clearance); Hepatic: 10-20% (degradation by insulinase); Fecal: <1%
Renal elimination of degradation products. Approximately 30-40% of insulin dose is excreted unchanged in urine; the remainder is metabolized primarily in liver and kidney and excreted as metabolites.
Category C
Category C
Insulin Analog
Insulin Analog